BIOCON.NS vs. NVO
Compare and contrast key facts about Biocon Limited (BIOCON.NS) and Novo Nordisk A/S (NVO).
Performance
BIOCON.NS vs. NVO - Performance Comparison
Loading graphics...
BIOCON.NS vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIOCON.NS Biocon Limited | -7.29% | 7.96% | 46.55% | -4.10% | -28.08% | -21.65% | 58.46% | -6.44% | 17.27% | 70.11% |
NVO Novo Nordisk A/S | -23.02% | -36.31% | -13.39% | 55.91% | 35.84% | 66.77% | 26.44% | 31.97% | -5.10% | 43.42% |
Different Trading Currencies
BIOCON.NS is traded in INR, while NVO is traded in USD. To make them comparable, the NVO values have been converted to INR using the latest available exchange rates.
Returns By Period
In the year-to-date period, BIOCON.NS achieves a -7.29% return, which is significantly higher than NVO's -23.02% return. Over the past 10 years, BIOCON.NS has outperformed NVO with an annualized return of 16.32%, while NVO has yielded a comparatively lower 8.67% annualized return.
BIOCON.NS
- 1D
- 1.19%
- 1M
- -5.86%
- YTD
- -7.29%
- 6M
- 5.41%
- 1Y
- 7.84%
- 3Y*
- 21.30%
- 5Y*
- -2.12%
- 10Y*
- 16.32%
NVO
- 1D
- -1.00%
- 1M
- 1.79%
- YTD
- -23.02%
- 6M
- -32.93%
- 1Y
- -38.98%
- 3Y*
- -17.48%
- 5Y*
- 8.73%
- 10Y*
- 8.67%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIOCON.NS vs. NVO — Risk / Return Rank
BIOCON.NS
NVO
BIOCON.NS vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Biocon Limited (BIOCON.NS) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BIOCON.NS | NVO | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.28 | -0.73 | +1.01 |
Sortino ratioReturn per unit of downside risk | 0.56 | -0.81 | +1.37 |
Omega ratioGain probability vs. loss probability | 1.07 | 0.89 | +0.19 |
Calmar ratioReturn relative to maximum drawdown | 0.39 | -0.79 | +1.18 |
Martin ratioReturn relative to average drawdown | 0.72 | -1.36 | +2.08 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| BIOCON.NS | NVO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.28 | -0.73 | +1.01 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.07 | 0.23 | -0.30 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.50 | 0.27 | +0.22 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.10 | 0.59 | -0.49 |
Correlation
The correlation between BIOCON.NS and NVO is 0.03, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
BIOCON.NS vs. NVO - Dividend Comparison
BIOCON.NS's dividend yield for the trailing twelve months is around 0.14%, less than NVO's 4.94% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIOCON.NS Biocon Limited | 0.14% | 0.13% | 0.14% | 0.60% | 0.19% | 0.00% | 0.00% | 0.17% | 0.16% | 0.19% | 0.53% | 0.97% |
NVO Novo Nordisk A/S | 4.94% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Drawdowns
BIOCON.NS vs. NVO - Drawdown Comparison
The maximum BIOCON.NS drawdown since its inception was -93.15%, which is greater than NVO's maximum drawdown of -71.61%. Use the drawdown chart below to compare losses from any high point for BIOCON.NS and NVO.
Loading graphics...
Drawdown Indicators
| BIOCON.NS | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.15% | -74.70% | -18.45% |
Max Drawdown (1Y)Largest decline over 1 year | -15.01% | -55.03% | +40.02% |
Max Drawdown (5Y)Largest decline over 5 years | -52.65% | -74.70% | +22.05% |
Max Drawdown (10Y)Largest decline over 10 years | -58.85% | -74.70% | +15.85% |
Current DrawdownCurrent decline from peak | -23.71% | -73.49% | +49.78% |
Average DrawdownAverage peak-to-trough decline | -49.21% | -17.56% | -31.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.06% | 31.83% | -23.77% |
Volatility
BIOCON.NS vs. NVO - Volatility Comparison
Biocon Limited (BIOCON.NS) has a higher volatility of 9.45% compared to Novo Nordisk A/S (NVO) at 8.72%. This indicates that BIOCON.NS's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| BIOCON.NS | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.45% | 8.72% | +0.73% |
Volatility (6M)Calculated over the trailing 6-month period | 17.50% | 39.06% | -21.56% |
Volatility (1Y)Calculated over the trailing 1-year period | 28.45% | 53.81% | -25.36% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 31.36% | 37.57% | -6.21% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 33.64% | 31.96% | +1.68% |
Financials
BIOCON.NS vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Biocon Limited and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities